Effect of Dutasteride on Intraprostatic Androgen Levels in Men With Benign Prostatic Hyperplasia or Prostate Cancer

Evaluation of Intravesical Prostatic Protrusion as a Predictor of Dutasteride-Resistant Lower Urinary Tract Symptoms/Benign Prostatic Enlargement With a High Likelihood of Surgical Intervention

“…11 When dutasteride is administered at a dose of 0.5 mg/day, the blood DHT level decreases to approximately 10% of the baseline value in the second week after administration. 12 Furthermore, the DHT level in prostate tissue decreases to a similar level, 13 and a reduction effect is seen on PV. According to the interim analysis of the Combination of Avodart and Tamsulosin (CombAT) study, IPSS was significantly improved by 3 months of combination therapy with a 1 -blockers and dutasteride.…”

SRD5A2 gene expression inhibits cell migration and invasion in prostate cancer cell line via F-actin reorganization

“…Although the increased expression of SRD5A2 has been implicated in the formation of benign prostate hyperplasia [9,10], the loss of its expression was noticed in androgen-insensitive metastatic cancer [8][9][10]. Drugs like Finasteride (a specific inhibitor of 5a-reductase-2) and dutasteride (inhibits both 5a-reductase-1 and -2) are successfully used in the clinics to decrease prostate volume in men with benign prostate hyperplasia [13][14][15][16][17]. However, the therapeutic efficacy of these drugs in advanced stage of the disease particularly during androgen deprivation therapy proved to be least beneficial and remains a controversial issue [18][19][20].…”

Effects of dutasteride on lower urinary tract symptoms and general health in men with benign prostatic hypertroplasia and hypogonadism: a prospective study

“…Dutasteride inhibits both isoforms of 5-AR, type 1 5-AR (found in the skin, gut, liver, and other tissues) and type 2 5-AR, which decreases serum concentrations of DHT by more than 90% and subsequently reduces prostate volume, thus improving lower urinary tract symptoms (LUTS) and overactive bladder (OAB) caused by BPH [1,3]. Furthermore, the dutasteride-induced decrease in serum DHT level contributes to an increase of approximately 18% in testosterone level [4].…”